Biologics are produced by using living system such as plant cell, micro-organism and animal cell and are regulated by U.S. FDA (United States Food and Drug Administration). Avastin, Lantus, Botox, Herceptin, Humira are some examples of Biologics.

New product approvals by FDA and presence of major key players has contributed in market growth. Growing prevalence of cancer diseases and rising demand for CDMOs from emerging pharmaceutical and biotech companies has boosted the target market's growth. The rise in the number of clinical trials is expected to fuel the Biologics CDMO market expansion.

The report “Biologics CDMO Market, By Type (Mammalian, Non-Mammalian), By Product Type (Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In January 2021, GenScript’s biologics CDMO subsidiary ProBio achieved its fundraising round in less than 2 years in which the CDMO’s will raise around $224 million to provide fuel for business expansion and for working capital for ProBio to develop manufacturing capacity with advanced research & development capabilities and thus, acquires assets to develop CDMO business.

• In December 2020, KBI Biopharma dropped $150 million in 140,000 sq.ft., commercial manufacturing facility in ‘Research Triangle Park’ at North Carolina for producing complex biologics which includes therapeutic proteins for unnamed pharmaceutical partner.

Analyst View:

Presence of major key players and new product launch has given positive impact on target market growth. Rising prevalence of cancer diseases and demand for advanced therapies has further facilitated the target market growth. CDMO ha top qualified researchers, engineers, chemists, R&D facilities and manufacturing staff which has given rise in Biologics CDMO market growth. Growing trend towards outsourcing manufacturing activities is expected to boost the demand for Biologics CDMO market growth in coming years.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Biologics CDMO Market, By Type (Mammalian, Non-Mammalian), By Product Type (Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Biologics CDMO Market accounted for US$ 18 billion in 2024 and is estimated to be US$ 55 billion by 2034 and is anticipated to register a CAGR of 11.80%. The Biologics CDMO Market is segmented based on Type, Product Type, and Region.

• Based on Type, Biologics CDMO Market is segmented into Mammalian, Non-Mammalian.

• Based on Product Type, Biologics CDMO Market is segmented into Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars.
• By Region, the Biologics CDMO Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Biologics CDMO Market:

The prominent players operating in the Biologics CDMO Market includes, Lonza Group, Catalent Inc., Samsung Biologics, Eurofins Scientific, Boehringer Ingelheim Group, FUJIFILM Diosynth Biotechnologies Inc., Wuxi Biologics, LabCorp Drug Development, Cambrex Corporation, AGC Biologics and others.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com